

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 March 2021 (18.03.2021)



(10) International Publication Number
WO 2021/050708 A1

(51) International Patent Classification:

A61P 31/04 (2006.01) A61K 31/496 (2006.01)
C07D 471/04 (2006.01) A61K 31/498 (2006.01)
A61K 31/437 (2006.01) A61K 31/499 (2006.01)
A61K 31/4545 (2006.01) A61K 31/4995 (2006.01)

(21) International Application Number:

PCT/US2020/050173

(22) International Filing Date:

10 September 2020 (10.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/898,066 10 September 2019 (10.09.2019) US

(71) Applicants: **SHIONOGI & CO., LTD.** [JP/JP];
1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
541-0045 (JP). **HSIRI THERAPEUTICS, INC.** [US/US];
1400 N. Providence Road, Building 1, Suite 115S, Media,
Pennsylvania 19063 (US).

(72) Inventors: **FUJITANI, Manabu**; c/o Shionogi & Co.,
Ltd., 1-1, Futaba-cho 3-chome, Toyonaka-shi, Osaka
561-0825 (JP). **IWAKI, Tsutomu**; c/o Shionogi & Co.,
Ltd., 1-1, Futaba-cho 3-chome, Toyonaka-shi, Osaka




561-0825 (JP). **NAKAMURA, Rina**; c/o Shionogi &
Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka-shi, Osaka
561-0825 (JP). **MILLER, Marvin J.**; 17885 Tally Ho Dr.,
South Bend, Indiana 46635 (US). **MORASKI, Garrett C.**;
122 Franklin Hills Rd., Bozeman, Montana 59715 (US).

(74) Agent: **FREISTEIN, Andrew B.**; 1025 Connecticut Av-
enue N.W., Suite 500, Washington, District of Columbia
20036 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION



(57) Abstract: A compound represented by formula (I); or its pharmaceuti-
cally acceptable salt, wherein a group represented by formula: (II) is a group
represented by formula: (III) or (IV); R¹ is each independently halogen, hy-
droxy, cyano or the like; m is 0, 1, 2, 3 or 4; R² is a hydrogen atom, halogen,
cyano, substituted or unsubstituted alkyl or the like; R^{3a}, R^{3b}, R^{3c} and R^{3d}
are each independently hydrogen atom, halogen or the like, with the proviso that
R^{3a}, R^{3b}, R^{3c} and R^{3d} are not simultaneously hydrogen atom; ring C is rep-
resented as follows: (V), (VI), (VII), (VIII), (IX) or (X). X is CH or N; Y is CH
or N; R⁴ is each independently halogen, hydroxy, cyano or the like; p is 0 or
1; q is 0, 1, 2, 3 or 4; R⁵ is CR^{5C} or N; R⁶ is CR^{6C} or N; R⁷ is CR^{7C} or N;
R⁸ is CR^{8C} or N; R⁹ is CR^{9C} or N; with the proviso that R⁵, R⁶, R⁷, R⁸ and R⁹
are not simultaneously N; R^{5C}, R^{6C}, R^{7C}, R^{8C} and R^{9C} are each independently
hydrogen atom or the like.

WO 2021/050708 A1

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))